Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Shareholder Meeting (July 2020)
20 slides from Theracryf's shareholder meeting presentation, Jul 16, 2020
Slide 1: Evgen Pharma plc AGM Presentation
EVGEN PHARMA PLC AGM Presentation 16 July 2020
Slide 2: Disclaimer
Disclaimer This document has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company” or “Evgen”) which trades on the AIM market of the London Stock Exchange under ticker EVG. By attending this presentation and/or reviewing the slides, you agree to be bound by the followin
Slide 3: Evgen is a clinical stage drug development company with impressive Phase II efficacy data
Evgen is a clinical stage drug development company with impressive Phase II efficacy data Focused on the development of a new class of pharmaceuticals - based on the bioactive compound sulforaphane Sulforaphane targets the STAT3 and Nrf2 pathways – of significance in oncology, inflammatory and f
Slide 4: Current status
Current status Strong data from Phase II trial of SFX-01 in metastatic breast cancer (mBC) Tumour shrinkage in difficult to treat patient population Five patients received SFX-01 treatment for over one year with no tumour progression Physicians have agreed to support follow-on trial Result
Slide 5: STAR trial (SFX-01 Treatment for Acute Respiratory Infections)
STAR trial (SFX-01 Treatment for Acute Respiratory Infections) Randomised Phase II/III trial sponsored by the University of Dundee Funded by LifeArc after competitive application process 300 patients with confirmed or suspected COVID-19; 50:50 active vs. placebo Evaluating if SFX-01 can redu
Slide 6: Evgen is the only company with a sulforaphane-based medicine in the clinic
Evgen is the only company with a sulforaphane- based medicine in the clinic Pure sulforaphane is a liquid that requires storage at minus 20oC to maintain stability, and therefore clinical trials have been precluded Sulforadex® technology enables scalable manufacturing of synthetic sulforaphane s
Slide 7: The significance of the Nrf2 & STAT3 pathways
The significance of the Nrf2 & STAT3 pathways
Slide 8: A compound that targets BOTH Nrf2 and STAT3 offers unique positioning
A compound that targets BOTH Nrf2 and STAT3 offers unique positioning Electrophilic compounds that bind to cysteine revenues can bind to Cancer target Nrf2 and STAT3 e.g. Fibrosis sulforaphane and bardoxolone IBD MASH Glioblastoma The chemistry behind the MoA is Autism1 thus common to both targe
Slide 9: The opportunity in metastatic breast cancer
The opportunity in metastatic breast cancer
Slide 10: What is the opportunity?
What is the opportunity ? ER+ breast cancer is the most prevalent breast cancer sub-type (70%) Metastatic breast cancer is incurable with 5-year survival rates of 22% Patients become resistant to all drugs SFX-01 is being developed to prevent and/or reverse resistance Our data on SFX-01 sh
Slide 11: SFX-01 can be life-changing
SFX-01 can be life-changing Diagnosed age 40 ER+ Her2- early BC Received surgery, chemotherapy and tamoxifen After 5 years diagnosed with pleural nodules Enrolled into STEM trial May 2017 – tamoxifen + SFX-01 Objective response to treatment, very well tolerated, able to continue her life c
Slide 12: STEM showed that SFX-01 shrinks tumours and halts tumour growth
STEM showed that SFX-01 shrinks tumours and halts tumour growth SFX-01 added to tamoxifen or fulvestrant SFX-01 added to endocrine therapy caused caused tumour shrinkage tumour stabilisation Note that patients had already progressed on their current therapy and remained on this, with SFX-01 adde
Slide 13: Current and planned work programme
Current and planned work programme All preclinical breast data published in high impact journal in June 2020 Extensive review of clinical pathway to approval close to completion Supplementary preclinical work required to confirm CDK4/6i “resistance-breaking” hypothesis New “commercial ready”
Slide 14: Broadening the clinical pipeline through investigator-led trials
Broadening the clinical pipeline through investigator-led trials
Slide 15: Potential Investigator-Led Clinical Collaborations
Potential Investigator-Led Clinical Collaborations "We are working with patient groups to plan a grant application for a Phase II clinical trial programme on SFX-01 in children with ASD, hoping to recruit from a consortium of UK hospitals. Our interest, and that of the parents of some children with
Slide 16: Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) No approved medicines for treating the three core symptoms of autism Encouraging clinical data from a small investigator-led placebo-controlled trial of juvenile patients in the US, using sulforaphane derived from botanical sources But no opportunity to move this
Slide 17: Metabolic Associated steatohepatitis (MASH)
Metabolic Associated steatohepatitis (MASH) Metabolic associated fatty liver disease (“MAFLD”) is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population 10%-20% of those with MAFLD have MASH and 20-30% of MASH patients are at risk of
Slide 18: Next steps and summary
Next steps and summary
Slide 19: Next steps and summary
Next steps and summary Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial Phase II/III trial in ARDS patients commencing shortly Reduce risk and increase probability of success by expanding breadth of clinical programmes: Grant-funded, investigator
Slide 20: Evgen Pharma plc
Evgen Pharma plc Correspondence address: The Colony Altrincham Road Wilmslow Cheshire SK9 4LY Registered office: Liverpool Science Park IC2 146 Brownlow Hill Liverpool L3 5RF www.evgen.com